Clinical Trial Update: Treatment of Metastatic Melanoma with Lenvatinib + Anti-PD1

View source ↗

Summary

A completed clinical trial evaluating the combination of lenvatinib with an anti-PD1 therapy for metastatic melanoma has finished.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-PD1 antibody
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Metastatic Melanoma | Status: COMPLETED